Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02910089 · ClinicalTrials.gov registry record · Phase 4
ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,400
- Enrollment target
NCT02910089 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 1,400 participants.
The verdict
NCT02910089, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,400 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether a combination of pharmacist-delivered patient engagement techniques improves disease control and medication adherence among patients with poorly-controlled diabetes compared with usual care. These engagement techniques include shared decision-making and brief negotiated interviewing and are delivered telephonically.
Interventions
- BEHAVIORAL Shared Decision Making
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,400 participants |
| Start Date | 2016-10-20 |
| Est. Completion | 2017-12-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02910089
The ClinicalTrials.gov registry entry for NCT02910089 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Shared Decision Making is the first listed.
NCT02910089 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02910089 about?
NCT02910089 is a clinical study titled "ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus". The purpose of this study is to evaluate whether a combination of pharmacist-delivered patient engagement techniques improves disease control and medication adherence among patients with poorly-controlled diabetes compared with usual care. These engagement techniques include shared decision-making a...
What is the current status of trial NCT02910089?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,400 participants. The study started on 2016-10-20. Estimated completion is 2017-12-20.
What interventions are being tested in trial NCT02910089?
The interventions under investigation include: Shared Decision Making (BEHAVIORAL).
Who is sponsoring clinical trial NCT02910089?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.